Evidence map›Paper›PMID 42436125›Full record

ArticleBlood cancer journal2026

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.

Jiadai Xu, Jing Li, Yuhong Ren, Luya Cheng, Zhixiang Cheng, Jingli Zhuang, Yang Ke, Shiyang Gu, Yian Zhang, Feifei Chen and 4 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jiadai XuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-6480-5607
Jing LiDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-9187-7809
Yuhong RenDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0003-0330-4125
Luya ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhixiang ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jingli ZhuangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yang KeDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Shiyang GuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yian ZhangDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Feifei ChenDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Rupan GaoDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Panpan LiDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yaqin XiongDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China. liu.peng@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-9639-6606

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82100215Natural Science Foundation of Fujian Province (Fujian Provincial Natural Science Foundation) 2023J05291
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42436125
PMCPMC13356022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.